Emerging Therapies Redefining the HR+/HER2- Breast Cancer Treatment Landscape
The treatment paradigm for HR+/HER2- breast cancer is evolving rapidly as innovative therapies advance through late-stage trials and enter clinical practice. Long-standing reliance on endocrine therapies and CDK4/6 inhibitors is being challenged by resistance and unmet patient needs. As a result, next-generation solutions such as oral SERDs, PROTACs, and novel antibody-drug conjugates are...
0 Kommentare 0 Geteilt 290 Ansichten 0 Bewertungen
Gesponsert